BioVersys and SARomics join efforts to combat multidrug-resistant bacterial infections

Antimicrobial resistance represents a major threat to public health worldwide and is far from being adequately addressed today, as evidenced by the low number of new products in clinical development. The SARTRIC project addresses this deficiency by restoring antibiotic activity by blocking the transcriptional activation of resistance genes with small molecules and thus restoring the efficacy of already marketed drugs.

The two SME (small/medium enterprise) partners BioVersys AG (Basel, Switzerland) and SARomics Biostructures AB (Lund, Sweden) will combine their highly complementary technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. Part of the project will be financed by a Eurostars grant. 

“It is a great pleasure to see the synergies between our two companies bearing fruit in an international collaboration with the support and funding of EUROSTARS.” explained Marcel Tigges, CSO at BioVersys.

“We are excited to collaborate with BioVersys on this potentially game-changing approach that addresses a high unmet medical need.” says Dr. Björn Walse, CEO at SARomics Biostructures.